Preparation and ocular pharmacokinetics of ganciclovir liposomes

AAPS Journal

Volumn 9, Issue 3, 2007, Pages

  Shen, Yan ^a   Tu, Jiasheng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Ganciclovir; Liposomes; Ocular pharmacokinetics; Precorneal clearance

Indexed keywords

GANCICLOVIR; LIPOSOME; ANTIVIRUS AGENT;

AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORNEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENCAPSULATION; EVAPORATION; IN VITRO STUDY; IN VIVO STUDY; IRIS; LENS; MEAN RESIDENCE TIME; RABBIT; SCLERA; TIME; VITREOUS BODY; ANIMAL; CHEMISTRY; FEMALE; MALE; METABOLISM;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CORNEA; FEMALE; GANCICLOVIR; LIPOSOMES; MALE; RABBITS;

EID: 38849166180     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0903044     Document Type: Article

References (19)

1. Mar E, Cheng Y, Huang Y. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1983;24:518-521.
2. Martin J, Dvorack C, Smee D, Matthews T, Verheyden J. 9-[(1,3-Dihydroxy-2-propoxy) methyl]guanine: a new potent and selective antiherpes agent. J Med Chem. 1983;26:759-761.
3. Cantrill H, Henry K, Melroe N, et al. Treatment of cytgmegalovirus retinitis with intravitreal ganciclovir, long-term results. Ophthalmology. 1989;96:367-174.
4. Markham A, Faulde D, Gancicliovir: an update of its therapeutic use in cytomegalo virus infection. Drugs. 1994;48;455-460.
5. Maudgal P, De Clercq K, Descamps J, Missotten L. Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir, a water-soluble ester of acyclovir. Arch Opthalmol. 1984;102:40-142.
6. Hughes P, Mitra A. Effect acylation on the ocular disposition of acyclovir. II: Corneal permeability and anti-HSV 1 activity of 29-esters in rabbit epithelial Keratitis. J Ocul Pharmacol. 1993;9:299-309.
7. Drew W. Is combination antiviral therapy for CMV superior to monotherapy? J Clin Virol. 2006;35:485-488.
8. Wiltink E, Stekkinger P, Brakenhoff J, Danner S, Determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHG) in biological fluids by reverse-phase high pressure liquid chromatography. Pharm Weekbl Sci. 1987;9:261-264.
9. Choonara Y, Pillay V, Carmichael T, et al. An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm. 2006;310:15-24.
10. Law S, Huang K, Chiang C. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. J Control Release. 2000;63:135-140.
11. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
12. Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA. 1978;75: 4194-4198.
13. Wu P. The characterization and biodistribution of cefoxitin-loaded liposomes. Int J Pharm. 2004;271:31-39.
14. Law S, Hung H. Properties of acyclovit-containing liposomes for potential ocular delivery. Int J Pharm. 1998;161:253-259.
15. Durrani A, Farr S, Kellaway I. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int J Pharm. 1995;118:243-250.
16. McSharry J, McDonough A, Olson B, et al. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol. 2001;8:1279-1281.
17. McCalden T, Levy M. Retention of topical liposomal formulation on the cornea. Experientia. 1990;46:713-715.
18. Pleyer U, Lutz S, Jusko W, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci. 1993;34:2737-2742.
19. Elsayed M, Abdallah O, Naggar V, et al. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322:60-66.